Overview

Cytomegalovirus Hyperimmune Globulin (CMV-Ig) Replacement in Hypogammaglobulinemic Lung Transplant Recipients

Status:
Completed
Trial end date:
2006-01-01
Target enrollment:
Participant gender:
Summary
This is a randomized controlled trial of CMV-Ig in lung transplant recipients at the Cleveland Clinic Foundation who are hypogammaglobulinemic.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
The Cleveland Clinic